Context-Dependent Translation Inhibition as a Novel Cancer Therapeutic Modality
Time: 3:15 pm
day: Conference Day Two
Details:
• Leveraging structure-based drug design to inhibit the translation of historically undruggable oncology targets, including MYC, with orally dosed small molecules called interdictors
• Developing hetero-bifunctional molecules called Interdictors that bind to the ribosome and prevent protein synthesis by engaging with the linear nascent polypeptide as it is being made
• Combining techniques of in vitro biochemistry, ribosome profiling, structural biology and cellular biology, we characterize the context-selective activity of several tool interdictors and how they inhibit cancer cell proliferation
• Demonstrating robust efficacy in the MDA-MB-231 model for TNBC, establishing interdiction as a novel small molecule therapeutic modality for addressing historically difficult-to-treat cancers
